| abstract |
In the general formula (I) of the compounds of the invention, R 1 is an optionally substituted 5-12 carbonyl cycloalkyl, indan-1-yl or indan-2-yl, decahydronaphthalen-1-yl, decahydronaphthalen-2-yl, decahydro-azylen-2-yl, bicyclo [6.2.0] dec-9-yl, acenaphthen-1-yl, bicyclo [3.1] nin-9-yl-2,3-dihydro-1H-phenalenyl -, 2,3,3a, 4,5,6-hexahydro-1H-phenalen-1-yl, octahydro-inden-2-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1,2,3,4-Tetrahydro-naphthalen-2-yl, naphthalen-alkyl-1-yl, naphthalen-alkyl-2-yl, or 5-isopropyl-2-methyl-bicyclo [3.1.0] hex -3-yl, R < 2 > and R < 3 > are hydrogen, hydroxy, alkyl, = O, or optionally a halogen, alkyl or alkoxy substituent, phenyl; (CH 2) n C 3-6 -cycloalkyl, phenyl, benzyl, tetrahydrofuran-3-yl- (CH 2) n OCH 2 C 6 H 5, - (CH 2) n -morpholinyl, 3-methyl-oxetan-3-ylmethyl- , - (CH 2) n CH 2 OH, -S (O) 2-alkyl piperidine, CO-alkyl piperidine, -C (O) CF 3, -C (O) - (CH 2) n OCH 3, - (CH 2) n C (O) N-acyl) 2, -S (O) 2 -heteroaryl, -C (O) heteroaryl, -S (O) 2-phenyl, S (O) 2-N-alkyl) 2-piperazin, -C (O) -cycloalkyl, -C (O) O -phenyl or -C (O) O-alkyltube, R5 is hydrogen, halogen, alkyl, trifluoromethyl or alkoxy, and n is 0-3). The invention also encompasses pharmaceutically acceptable acid addition salts of the compounds. The compounds of the present invention are useful in the treatment of azo-fanin FQ (OFQ) receptor-related disorders, such as psychiatric, neuro-viral and physiological disorders, in particular the treatment of depression, trauma, Alzheimer's disease and other dementias, depression, trauma, , epilepsy and stone ulcers, acute and / or chronic pain conditions, post-herpetic loss symptoms, water balance control, Na + secretion, arterial hypertension disorders and metabolic disorders (eg, obesity.) |